Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Alfa vs rHuEPO for Chemotherapy-Induced Anemia
NCT00038064Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2002
- Primary completion
- Oct 2003
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoint: Time to first hemoglobin response during the treatment period. Started Jan 2002; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00038064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038064.